vs
豪洛捷（HOLX）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是豪洛捷的1.4倍（$1.4B vs $1.0B），豪洛捷净利率更高（17.1% vs -22.3%，领先39.4%），罗布乐思同比增速更快（43.2% vs 2.5%），罗布乐思自由现金流更多（$308.6M vs $215.2M），过去两年罗布乐思的营收复合增速更高（32.9% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
HOLX vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.4倍
$1.0B
营收增速更快
RBLX
高出40.6%
2.5%
净利率更高
HOLX
高出39.4%
-22.3%
自由现金流更多
RBLX
多$93.4M
$215.2M
两年增速更快
RBLX
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.4B |
| 净利润 | $179.1M | $-316.0M |
| 毛利率 | 56.0% | 77.7% |
| 营业利润率 | 22.6% | -25.3% |
| 净利率 | 17.1% | -22.3% |
| 营收同比 | 2.5% | 43.2% |
| 净利润同比 | -10.9% | -43.9% |
| 每股收益（稀释后） | $0.79 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRBLX
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.0B | $1.0B | ||
| Q4 24 | $1.0B | $988.2M | ||
| Q3 24 | $988.0M | $919.0M | ||
| Q2 24 | $1.0B | $893.5M | ||
| Q1 24 | $1.0B | $801.3M |
净利润HOLXRBLX
| Q4 25 | $179.1M | $-316.0M | ||
| Q3 25 | $187.2M | $-255.6M | ||
| Q2 25 | $194.9M | $-278.4M | ||
| Q1 25 | $-17.4M | $-215.1M | ||
| Q4 24 | $201.0M | $-219.6M | ||
| Q3 24 | $178.6M | $-239.3M | ||
| Q2 24 | $194.5M | $-205.9M | ||
| Q1 24 | $169.9M | $-270.6M |
毛利率HOLXRBLX
| Q4 25 | 56.0% | 77.7% | ||
| Q3 25 | 55.6% | 78.2% | ||
| Q2 25 | 56.3% | 78.2% | ||
| Q1 25 | 37.5% | 78.3% | ||
| Q4 24 | 56.8% | 77.9% | ||
| Q3 24 | 56.4% | 77.7% | ||
| Q2 24 | 55.4% | 77.8% | ||
| Q1 24 | 53.3% | 77.7% |
营业利润率HOLXRBLX
| Q4 25 | 22.6% | -25.3% | ||
| Q3 25 | 22.6% | -21.8% | ||
| Q2 25 | 24.9% | -29.8% | ||
| Q1 25 | -0.7% | -24.6% | ||
| Q4 24 | 22.5% | -24.7% | ||
| Q3 24 | 23.3% | -30.4% | ||
| Q2 24 | 24.1% | -26.6% | ||
| Q1 24 | 20.7% | -37.7% |
净利率HOLXRBLX
| Q4 25 | 17.1% | -22.3% | ||
| Q3 25 | 17.8% | -18.8% | ||
| Q2 25 | 19.0% | -25.8% | ||
| Q1 25 | -1.7% | -20.8% | ||
| Q4 24 | 19.7% | -22.2% | ||
| Q3 24 | 18.1% | -26.0% | ||
| Q2 24 | 19.2% | -23.0% | ||
| Q1 24 | 16.7% | -33.8% |
每股收益（稀释后）HOLXRBLX
| Q4 25 | $0.79 | $-0.44 | ||
| Q3 25 | $0.84 | $-0.37 | ||
| Q2 25 | $0.86 | $-0.41 | ||
| Q1 25 | $-0.08 | $-0.32 | ||
| Q4 24 | $0.87 | $-0.32 | ||
| Q3 24 | $0.75 | $-0.37 | ||
| Q2 24 | $0.82 | $-0.32 | ||
| Q1 24 | $0.72 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $3.1B |
| 总债务越低越好 | $2.5B | $1.2B |
| 股东权益账面价值 | $5.2B | $394.5M |
| 总资产 | $9.2B | $9.6B |
| 负债/权益比越低杠杆越低 | 0.48× | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRBLX
| Q4 25 | $2.4B | $3.1B | ||
| Q3 25 | $2.2B | $2.9B | ||
| Q2 25 | $1.9B | $2.6B | ||
| Q1 25 | $1.6B | $2.7B | ||
| Q4 24 | $2.0B | $2.4B | ||
| Q3 24 | $2.3B | $2.3B | ||
| Q2 24 | $2.4B | $2.4B | ||
| Q1 24 | $2.2B | $2.4B |
总债务HOLXRBLX
| Q4 25 | $2.5B | $1.2B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
股东权益HOLXRBLX
| Q4 25 | $5.2B | $394.5M | ||
| Q3 25 | $5.0B | $407.6M | ||
| Q2 25 | $4.8B | $353.2M | ||
| Q1 25 | $4.6B | $310.7M | ||
| Q4 24 | $4.8B | $221.4M | ||
| Q3 24 | $5.1B | $189.9M | ||
| Q2 24 | $5.0B | $121.5M | ||
| Q1 24 | $4.8B | $71.6M |
总资产HOLXRBLX
| Q4 25 | $9.2B | $9.6B | ||
| Q3 25 | $9.0B | $8.6B | ||
| Q2 25 | $8.8B | $7.8B | ||
| Q1 25 | $8.5B | $7.5B | ||
| Q4 24 | $8.7B | $7.2B | ||
| Q3 24 | $9.2B | $6.7B | ||
| Q2 24 | $8.9B | $6.5B | ||
| Q1 24 | $8.7B | $6.3B |
负债/权益比HOLXRBLX
| Q4 25 | 0.48× | 2.98× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 5.48× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $308.6M |
| 自由现金流率自由现金流/营收 | 20.5% | 21.8% |
| 资本支出强度资本支出/营收 | 1.4% | 21.1% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $1.4B |
8季度趋势，按日历期对齐
经营现金流HOLXRBLX
| Q4 25 | $229.9M | $607.0M | ||
| Q3 25 | $355.1M | $546.2M | ||
| Q2 25 | $343.3M | $199.3M | ||
| Q1 25 | $169.4M | $443.9M | ||
| Q4 24 | $189.3M | $184.5M | ||
| Q3 24 | $367.0M | $247.4M | ||
| Q2 24 | $405.8M | $151.4M | ||
| Q1 24 | $292.4M | $238.9M |
自由现金流HOLXRBLX
| Q4 25 | $215.2M | $308.6M | ||
| Q3 25 | $341.4M | $443.6M | ||
| Q2 25 | $330.5M | $176.7M | ||
| Q1 25 | $153.9M | $426.5M | ||
| Q4 24 | $172.5M | $120.6M | ||
| Q3 24 | $350.6M | $218.0M | ||
| Q2 24 | $385.3M | $111.7M | ||
| Q1 24 | $279.6M | $192.3M |
自由现金流率HOLXRBLX
| Q4 25 | 20.5% | 21.8% | ||
| Q3 25 | 32.5% | 32.6% | ||
| Q2 25 | 32.3% | 16.3% | ||
| Q1 25 | 15.3% | 41.2% | ||
| Q4 24 | 16.9% | 12.2% | ||
| Q3 24 | 35.5% | 23.7% | ||
| Q2 24 | 38.1% | 12.5% | ||
| Q1 24 | 27.5% | 24.0% |
资本支出强度HOLXRBLX
| Q4 25 | 1.4% | 21.1% | ||
| Q3 25 | 1.3% | 7.5% | ||
| Q2 25 | 1.3% | 2.1% | ||
| Q1 25 | 1.5% | 1.7% | ||
| Q4 24 | 1.6% | 6.5% | ||
| Q3 24 | 1.7% | 3.2% | ||
| Q2 24 | 2.0% | 4.4% | ||
| Q1 24 | 1.3% | 5.8% |
现金转化率HOLXRBLX
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RBLX
暂无分部数据
